Group 1 - Banqiao Qiancheng signed a significant contract with Mango Film and Television for a total amount of 372 million yuan, accounting for 50.65% of the company's audited main business income for 2024 [1] - The contract allows Mango Film and Television to use the new media and traditional media broadcasting rights for related film and television works globally, positively impacting Banqiao Qiancheng's financial status and operating performance in 2025 and beyond [1] - Jingwei Huikai plans to sell its wholly-owned subsidiary Changsha Yushun for 112 million yuan, which will no longer be included in the consolidated financial statements after the transaction [1] Group 2 - Minsheng Health's subsidiary received a patent for a strain of lactic acid bacteria that significantly improves sarcopenic obesity, although it has not yet been applied to the company's products [2] - Dafu Technology intends to transfer 27% of its subsidiary Shenzhen Peitian Intelligent Manufacturing Equipment Co., Ltd. for 192 million yuan, maintaining a controlling stake post-transaction [3] - Feilong Co. received orders for high-power electronic water pumps for data centers from a well-known global power electronics provider [4] Group 3 - Yatai Co. was selected as a supplier for a foreign brand's EPB project, with a total sales amount of approximately 680 million yuan over a five-year lifecycle [5] - Gansu Energy's 1 million kilowatt wind-solar integrated project has received approval, representing over 10% of the company's installed capacity by the end of 2024 [6] - Jilin Aodong's subsidiary received approval for a drug supplement application for "Tang Le Capsule," used to treat symptoms related to diabetes [7] Group 4 - Shanshui Technology plans to invest 6 billion yuan in a new chemical materials project, expected to generate an annual output value of 8 billion yuan upon completion [8] - Dazhu CNC's H-share issuance application has been accepted by the China Securities Regulatory Commission [9] - Zhujiang Beer announced the resignation of its chairman due to retirement age, with a new chairman elected on the same day [10] Group 5 - Longkun Technology won a bid for a waste collection service project worth 21.57 million yuan, with a service period of one year [11] - Zhongnan Culture plans to provide financial support of up to 20 million yuan to its subsidiary for daily operational needs [12] - Shangfeng Cement's investment in a company applying for an IPO on the Sci-Tech Innovation Board has been accepted [13] Group 6 - Chuanheng Co. received a patent for a system and method for harmless treatment of phosphorus tailings [14] - Toukeng Life's seven medical device registration applications have been accepted, covering various diagnostic fields [15] - Xingqi Eye Medicine's clinical trial for a new eye gel has commenced with the first subject enrolled [16] Group 7 - Jiebang Technology plans to provide financial support of up to 60 million yuan to its subsidiary for operational needs [17] - Shenzhen Airport reported a passenger throughput of 5.54 million in May, a year-on-year increase of 15.67% [18] - Wan'an Technology received a cash dividend of 30 million yuan from its wholly-owned subsidiary [19] Group 8 - Jiuchuan Bio received a medical device registration certificate for a cystatin C assay kit [20] - Hongqiang Co. obtained a safety production license for its subsidiary, marking the official production of a new project [21] - Xiangtan Electric plans to issue convertible bonds totaling 487 million yuan [22] Group 9 - Guangwei Composite signed a supplementary material procurement contract worth 658 million yuan [23] - Jichuan Pharmaceutical announced a comprehensive tender offer starting June 18, with a price of 26.93 yuan per share [24] - Aerospace Rainbow plans to distribute cash dividends of 0.60 yuan per share [25] Group 10 - Industrial Bank plans to distribute cash dividends of 1.06 yuan per share, totaling 22.433 billion yuan [26] - China Automotive Research will repurchase and cancel 230,800 restricted shares due to the retirement of original incentive objects [27] - Annie Co. announced abnormal stock trading fluctuations but confirmed no significant changes in its operations [28] Group 11 - Giant Network confirmed no undisclosed significant matters following abnormal stock trading fluctuations [29]

Core Viewpoint - The company has initiated the Phase III clinical trial for its lidocaine hydrochloride eye gel, which is intended for surface anesthesia in ophthalmic procedures, following the successful enrollment of the first subject in a randomized, double-blind, positive drug parallel control, and placebo parallel control multi-center clinical trial [1] Summary by Relevant Sections - **Product Development** - The lidocaine hydrochloride eye gel is designed to enhance the effectiveness of anesthesia by prolonging the contact time with the eye surface [1] - This product is currently the only one approved for market by Sichuan Heyi Pharmaceutical Co., Ltd. [1] - **Clinical Trial Progress** - The company has completed the enrollment of the first subject in the Phase III clinical trial, marking a significant milestone in the product's development [1] - The trial aims to evaluate the efficacy and safety of the eye gel for surface anesthesia [1] - **Financial Impact** - The initiation of the Phase III clinical trial is not expected to have a significant impact on the company's recent financial performance [1]

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-030 沈阳兴齐眼药股份有限公司 关于盐酸利多卡因眼用凝胶Ⅲ期临床试验首例受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的盐酸利多卡因眼用 凝胶于今日完成了"评价盐酸利多卡因眼用凝胶用于眼表麻醉的有效性和安全性 的随机、双盲、阳性药平行对照、安慰剂平行对照、多中心临床试验"的首例受 试者入组，正式进入Ⅲ期临床试验。现将有关内容公告如下： 一、基本情况 药物名称：盐酸利多卡因眼用凝胶 注册分类：化学药品 3 类 二、临床试验相关情况 盐酸利多卡因是一种酰胺类局部麻醉药，被广泛用于浸润麻醉、硬膜外麻醉、 表面麻醉及神经传导阻滞。盐酸利多卡因眼用凝胶可延长药物与眼表面接触时间， 改善麻醉效果。 盐酸利多卡因眼用凝胶Ⅲ期临床试验为一项随机、双盲、阳性药平行对照、 安慰剂平行对照、多中心临床试验，以评价盐酸利多卡因眼用凝胶用于眼表麻醉 的有效性和安全性。 三、同类药品的情况 1 本次公告的盐酸利多卡因眼用凝胶是以盐酸利多卡因为活性成份的眼用 ...

Core Viewpoint - The A-share market has experienced significant structural changes over the past decade, with only a few industries surpassing their historical highs from 2015, while a select group of companies have demonstrated strong growth potential despite overall index stagnation [1][2]. Industry Performance - The top three performing industries from June 2015 to June 2025 are Food & Beverage, Home Appliances, and Banking, with most other industries failing to exceed their 2015 peak levels [1]. - Over the past ten years, more than 170 leading stocks in sectors such as Communication, Electronics, Biomedicine, and Machinery have achieved cumulative gains exceeding 300%, driven by macroeconomic transformation and industrial upgrades [2]. - The Food & Beverage sector has shown resilience due to its essential consumption characteristics, with leading companies in sub-sectors like liquor and snacks significantly outperforming major indices [4][6]. Notable Stocks - The top five stocks in the Food & Beverage sector over the past decade include: - Salted Fish (盐津铺子): 1,430.52% - Shanxi Fenjiu (山西汾酒): 863.43% - Kweichow Moutai (贵州茅台): 629.72% - Wanchen Group (万辰集团): 588.50% - Dongpeng Beverage (东鹏饮料): 572.38% [5][6]. - In the Home Appliances sector, Midea Group (美的集团) has led with a cumulative increase of 292.31% since 2015, while other notable companies have also seen significant gains [6]. Banking Sector Insights - The banking sector has outperformed many expectations, with the banking index reaching a historical high of 7,237.72 points, reflecting an 11.66% increase year-to-date and a 61.4% increase since last year [11]. - Notably, 39 out of 42 banking stocks have risen this year, with a significant portion of banks achieving over 200% growth since 2015 [11][12]. - The top-performing bank, China Merchants Bank, has seen a cumulative increase of 224.14%, while major state-owned banks have also doubled in value over the same period [12].

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 关于沈阳兴齐眼药股份有限公司 2025 年第一次临时股东大会的法律意见书 致：沈阳兴齐眼药股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》（以下简称 "《公司法》"）以及中国证券监督管理委员会颁布的《上市公司股东会规则》 （以下简称"《股东会规则》"）的规定，北京市竞天公诚律师事务所（以下 简称"本所"）指派律师出席了沈阳兴齐眼药股份有限公司（以下简称"公 司"）2025年第一次临时股东大会（以下简称"本次股东大会"），并就本次 股东大会的有关事宜出具本法律意见书。 本所在此同意，公司可以将本法律意见书作为本次股东大会公告的法定文 件，随其他公告文件一并提交深圳证券交易所予以审核公告。 本所律师根据《股东会规则》第六条的要求，按照律师行业公认的业务标 准、道德规范和勤勉尽责精神，对本次股东大会召集和召开的有关事实及公司 提供的文件进行了核查和验证，现出具法律意见如下： 一、本次股东大会的召集、召开程序 1、本次股东大 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-029 沈阳兴齐眼药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开方式：本次会议以现场投票与网络投票相结合的方式召开。 2、现场会议时间：2025年6月13日（星期五）下午14:30。 3、网络投票时间：2025年6月13日，其中，通过深圳证券交易所交易系统进 行网络投票的具体时间为2025年6月13日9:15—9:25，9:30—11:30和13:00— 15:00；通过深圳证券交易所互联网投票系统进行网络投票的时间为2025年6月13 日9:15至15:00期间的任意时间。 4、现场会议召开地点：沈阳市浑南区泗水街68号，沈阳兴齐眼药股份有限 公司E1号楼，二楼多功能厅。 8、公司董事、监事、高级管理人员以及北京市竞天公诚律师事务所委派的 见证律师以现场的方式出席和列席了本次股东大会。 9、本次股东 ...

Core Viewpoint - The company Xingqi Eye Medicine, which previously dominated the market with its unique "myopia miracle drug" atropine sulfate eye drops, is now facing unprecedented competition as major players like Heng Rui Medicine and Zhao Ke Ophthalmology have received approval for similar products, threatening its market position [1][2]. Group 1: Market Competition - The approval of 0.01% atropine sulfate eye drops in March 2024 significantly boosted Xingqi's revenue, with eye drop sales soaring by 106% to 1.366 billion yuan, contributing over 10% to total revenue [2]. - Competitors such as Heng Rui Medicine and Zhao Ke Ophthalmology are advancing with their own products, with Heng Rui's subsidiary having a substantial sales force of 8,910 compared to Xingqi's 1,197, indicating a potential market share threat [2]. Group 2: Financial Performance - Xingqi's financial performance has been volatile, with net profit soaring by 208% in 2019 due to internal sales rights, but growth slowed to 12.55% in 2022 following new regulations on online prescription drug sales [3]. - The company reported a resurgence in growth of 44.54% in 2024 after the approval of its product, but acknowledged risks of slowing growth and declining market share as the product becomes more widely available [3]. Group 3: Cash Flow and Funding Challenges - The company has invested over 600 million yuan in R&D from 2022 to 2024, representing more than 12% of its revenue, but cash reserves have plummeted from 515 million yuan to 370 million yuan, with short-term loans increasing by 185% to 200 million yuan [4]. - To address its financial challenges, the founder Liu Jidong has opted to dilute his stake through a fundraising effort of 850 million yuan, reducing his ownership from 28.63% to 22.02%, marking the second significant financing attempt in four years [4].

Market Overview - As of 10:30 AM today, the Shanghai Composite Index stands at 3352.43 points, above the six-month moving average, with a change of 0.15% [1] - The total trading volume of A-shares today is 568.946 billion yuan [1] Stocks Performance - A total of 138 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Dahongli (300865) with a deviation rate of 17.40%, closing at 27.74 yuan, up 19.98% [1] - Huaxi Biological (688363) with a deviation rate of 6.97%, closing at 54.41 yuan, up 7.87% [1] - *ST Chengchang (001270) with a deviation rate of 5.20%, closing at 36.55 yuan, up 5.00% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Zhejiang Shuwenhua (600633) with a deviation rate of 5.17%, closing at 13.62 yuan, up 5.66% [1] - Gehua Cable (600037) with a deviation rate of 4.76%, closing at 7.73 yuan, up 6.47% [1] - Stocks with smaller deviation rates that have just crossed the six-month line include Aotai Biological, Chitianhua, and Emei Mountain A [1]

沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的 SQ-22031 滴眼液近 日获得了"评估 SQ-22031 滴眼液在健康受试者中单次/多次给药的安全性、耐受 性和药代动力学的单中心、随机、双盲、安慰剂对照的 I 期临床试验"临床研究 报告。根据《深圳证券交易所上市公司自律监管指引第 4 号——创业板行业信息 披露》的有关规定，现将主要内容公告如下： 一、基本情况 证券代码：300573 证券简称：兴齐眼药 公告编号：2025-028 沈阳兴齐眼药股份有限公司 关于 SQ-22031 滴眼液取得 I 期临床研究报告的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本次公告的 SQ-22031 滴眼液适应症为神经营养性角膜炎。截至本公告披露 日，经查询国家药品监督管理局网站，尚无同品种药品批准上市。 1 药品名称：SQ-22031 滴眼液 剂型：滴眼剂 注册分类：治疗用生物制品 1 类 适应症：神经营养性角膜炎 临床试验批准通知书编号：2024LP01687、2024LP01688、2024LP01689、 2024LP01690 临床试验分期： ...

Core Viewpoint - Xingqi Eye Pharmaceutical is actively enhancing its technological capabilities and research and development (R&D) capacity through a planned stock issuance to raise up to 850 million yuan for R&D center construction and working capital supplementation [1][2][4]. Fundraising and Investment - The company plans to issue shares to specific investors, raising no more than 850 million yuan, with the net proceeds allocated entirely to the R&D center project and working capital [2][3]. - The stock issuance will not exceed 30% of the total share capital prior to the issuance, amounting to a maximum of 73.6 million shares [2]. - The R&D center aims to create a benchmark in the ophthalmology field, integrating smart laboratory matrices and collaborative innovation platforms, with a total investment of 984 million yuan [3]. Financial Performance - Xingqi Eye Pharmaceutical has achieved continuous growth in revenue and net profit for six consecutive years from 2019 to 2024 [1][6]. - In Q1 2025, the company reported a revenue of 536 million yuan, a year-on-year increase of 53.24%, and a net profit of 146 million yuan, soaring by 319.86% [6][7]. - The gross margin for Q1 2025 reached 80.16%, an increase of 4.06 percentage points year-on-year, while the net margin was 27.21%, up by 17.28 percentage points [7]. R&D Focus and Team - The company emphasizes R&D as the core driver of its development, holding 72 invention patents and 60 approved ophthalmic drug numbers, with 38 products included in the medical insurance directory [4][5]. - As of December 31, 2024, the company had 271 R&D personnel, accounting for 11.17% of the total workforce, with a significant portion holding master's degrees or higher [5]. Market Position and Strategy - Xingqi Eye Pharmaceutical is recognized as a leading domestic company in ophthalmic drug R&D, with a diverse product line covering various categories of eye medications [6]. - The company aims to enhance its competitive edge through differentiated innovation and to establish itself as an innovation-driven pharmaceutical enterprise [4].